Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been shown to provide renal protection in patients with chronic kidney disease (CKD), regardless of their diabetes status. After initiation, a transient decrease in estimated glomerular filtration rate (eGFR), known as the “initial dip,” is commonly observed; however, its clinical significance remains uncertain. The aim of this study is to identify the factors that influence the magnitude of initial dip, to elucidate its relationship with long-term renal outcomes and changes in eGFR slope subsequent to SGLT2i initiation, and to investigate the factors associated with improvement in eGFR slope after SGLT2i initiation..
We conducted a single-center retrospective cohort study including CKD patients who newly initiated SGLT2i therapy between August 2019 and May 2023. Eligible patients had a baseline eGFR <90 mL/min/1.73 m² and at least 12 months of eGFR data before and after initiation. The initial dip was defined as the difference between baseline eGFR and the lowest eGFR observed within two months after initiation. eGFR slopes before and after treatment were estimated using a linear mixed-effects model. Multivariable regression analysis identified factors associated with the dip and with changes in eGFR slope.
A total of 195 patients were included (mean age 69.1 ± 12.3 years; mean baseline eGFR 41.4 ± 17.7 mL/min/1.73 m²; 47% with diabetes). The mean initial dip was −2.61 ± 3.91 mL/min/1.73 m² (−6.6 ± 8.7%). Only baseline eGFR was significantly associated with the dip magnitude. The mean eGFR slope improved significantly from −1.62 to −0.87 mL/min/1.73 m²/year after SGLT2i initiation (p < 0.01), irrespective of dip size. Patients who had a rapid eGFR decline before treatment showed a more significant improvement in the post-treatment slope.
SGLT2 inhibitors significantly attenuated eGFR decline in CKD patients. The initial dip, determined by the lowest eGFR within two months, was associated with baseline eGFR but not with long-term renal outcomes. Patients with faster rate of decline in kidney function prior to intervention may be more likely to benefit from SGLT2 inhibitors.
